Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

East Hanover, New Jersey 07936


This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.


Inclusion Criteria: - Outpatients ≥18 years of age. - Patients with a diagnosis of Stage II hypertension, defined as msSBP ≥ 160 mmHg and < 180 mmHg at Visit 2. Exclusion Criteria: - Severe hypertension defined as msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg. - Secondary form of hypertension. - Current diagnosis of heart failure (NYHA Class II-IV). - Current angina pectoris requiring pharmacological therapy (other than stable doses of oral or topical nitrates). - Second or third degree heart block without a pacemaker. - Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial fibrillation or atrial flutter, during the 12 months prior to Visit 1. - Clinically significant valvular heart disease. - Previous history of hypertensive encephalopathy or stroke, TIA, heart attack, coronary bypass surgery or any PCI. - Known Keith-Wagener grade III or IV hypertensive retinopathy. - In the month prior to Visit 1, patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications. - Patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications. - Inability to discontinue prior antihypertensive or other CV medications as required by the protocol. - Patients with Type 1 diabetes mellitus. - Patients with Type 2 diabetes mellitus not well controlled . - Elevated Serum potassium (over 5.3 mEq/L (mmol/L). - Any surgical or medical condition or the use of any medication which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs. Other protocol-defined inclusion/exclusion criteria may apply.



Primary Contact:


Backup Contact:


Location Contact:

East Hanover, New Jersey 07936
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.